(secondQuint)A Study of TMC207 in Patients With Moderately Impaired Hepatic Function.

 This is a Phase I, open label (all people know the identity of the intervention) study of TMC207.

 The study consists of a screening period and a 4-weeks treatment period.

 Sixteen participants will be enrolled in two panels.

 Panel A will include 8 patients of moderate hepatic impairment and Panel B will include 8 healthy participants.

 Safety evaluations including adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination will be monitored throughout the study.

 The entire study duration for each participant will be approximately 7 weeks.

.

 A Study of TMC207 in Patients With Moderately Impaired Hepatic Function@highlight

The purpose of this study is to assess the pharmacokinetics (what the body does to the medication), safety and tolerability of TMC207 and its N-monodesmethyl metabolite (M2) in healthy participants and in patients with moderate hepatic impairment after administration of a single 400 mg dose of TMC207.

